AVDL - Avadel Pharmaceuticals plc
(NaN%)
We couldn't determine Recommendation based on the data we have.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Avadel Pharmaceuticals plc (AVDL) - www.avadel.com
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.Exchange - NASDAQ
Industry - Medicinal and Botanical Manufacturing
Sector - Manufacturing
CEO - Gregory Divis
Employees - 2,020
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.